Glioblastoma Multiforme of Brain
34
11
16
8
Key Insights
Highlights
Success Rate
73% trial completion
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 49/100
8.8%
3 terminated out of 34 trials
72.7%
-13.8% vs benchmark
3%
1 trials in Phase 3/4
50%
4 of 8 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 8 completed trials
Clinical Trials (34)
Safety & Efficacy of DC Vaccine and TMZ for the Treatment of Newly-diagnosed Glioblastoma After Surgery
A Phase 1 Safety and Dose Finding Study of GLIX1 in Adults With Recurrent or Progressive High-grade Glioma
Immunogene-modified T (IgT) Cells Against Glioblastoma Multiforme
Trial of Niraparib in Participants With Newly-diagnosed Glioblastoma and Recurrent Glioma
CAR T Cells in Patients With MMP2+ Recurrent or Progressive Glioblastoma
GPC-3 CAR T CELLS FOR Recurrent GPC-3 Positive Glioblastoma
Neuro-pharmacological Properties of Repurposed Posaconazole in Glioblastoma: A Phase 0 Clinical Trial
Re-Administration of C134 in Patients With Recurrent GBM (C134-HSV-1)
Neuro-pharmacological Properties of Repurposed Ketoconazole in Glioblastomas
Ruxolitinib With Radiation and Temozolomide Compared to Radiation and Temozolomide for Newly Diagnosed Glioblastoma
Multitracer [18F]Fluciclovine and 18F-FDG PET, and Advanced MRI for Metabolic Profiling of Glioblastoma
Focused Ultrasound Blood-Brain Barrier Disruption for the Treatment of High-Grade Glioma in Patients Undergoing Standard Chemotherapy
Trial of C134 in Patients With Recurrent GBM
Study of Neoantigen-specific Adoptive T Cell Therapy for Newly Diagnosed MGMT Negative Glioblastoma Multiforme (GBM)
Avelumab in Patients With Newly Diagnosed Glioblastoma Multiforme
Pembrolizumab in Association With the IMA950/Poly-ICLC for Relapsing Glioblastoma
Laparoscopically Harvested Omental Free Tissue Autograft to Bypass the Blood Brain Barrier (BBB) in Human Recurrent Glioblastoma Multiforme (rGBM)
[18F]FPIA PET-CT in Glioblastoma Multiforme (GBM)
Multi Peptide Vaccination with XS15 in Addition to Standard Postoperative Radiation Therapy and Temozolomide Chemotherapy in Newly Diagnosed Glioblastoma
Omental Tissue Autograft in Human Recurrent Glioblastoma Multiforme (rGBM)